乐普医疗：医美业务进展超预期，“童颜针”含税收入已达1亿左右

Core Insights - The company has reported rapid growth in its medical aesthetics business, with revenue from its "童颜针" product reaching approximately 1 billion yuan since its launch in early August, exceeding expectations [1] - The product has been adopted by over 80% of large chain medical aesthetic institutions and around 1,500 to 2,000 small to medium-sized medical aesthetic institutions [1] - The company aims to achieve a revenue target of 1 billion yuan for its medical aesthetics segment by 2026 [1] Business Development - The "童颜针" product is noted for its excellent biocompatibility and low adverse reaction rate, receiving positive feedback from consumers [1] - Future promotional efforts will include partnerships with platforms like Meituan and the introduction of shareholder discounts for light medical aesthetic services [1]